USPTO Examiner FAY ZOHREH ALEMZADEH - Art Unit 1617

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18792849Methods of administering safe colon cleansing compositionsAugust 2024February 2025Allow710NoNo
18743526Methods of administering safe colon cleansing compositionsJune 2024December 2024Allow720YesNo
18711575INTRAVITREAL CORTICOSTEROID EXTENDED RELEASE IMPLANT AND METHODS OF USEMay 2024May 2025Allow1211YesNo
18659629AQUEOUS LIQUID PREPARATIONMay 2024January 2025Allow811YesNo
18425024GRANULATED AGRICULTURAL ADJUVANT AND METHOD OF MAKING AND USING SAMEJanuary 2024January 2025Allow1110NoNo
18360372GEL BASE COMPOSITION FOR COMPOUNDING INTO A MUCOADHESIVE DELIVERY SYSTEMJuly 2023April 2025Abandon2130YesNo
18336958TOBACCO LEAF FOLIAR SPRAYING SUBSTANCE AND METHOD FOR REDUCING HARMFUL INGREDIENTS IN CHEROOT AND TOBACCO SHREDSJune 2023March 2024Allow920NoNo
18189284SYSTEMS AND METHODS FOR APPLICATION OF ACTIVE INGREDIENTS TO CANNABISMarch 2023June 2024Abandon1510NoNo
17985058DIVALENT METAL-CONTAINING BIOMATERIALS AND METHODS OF USENovember 2022May 2025Abandon3010NoNo
17968113USE OF TT-10-LOADED NANOPARTICLES FOR CARDIAC REPAIROctober 2022October 2024Abandon2410NoNo
18045059COMPOSITIONS AND METHODS FOR ENHANCING WNT SIGNALING FOR TREATING CANCEROctober 2022May 2025Allow3121YesNo
17951986USE OF 4-(PHENYLETHYNYL) BENZOIC ACIDSeptember 2022March 2024Allow1820NoNo
17935065Low Viscosity Agricultural Adjuvant for Spraying Syrups and Method of ProductionSeptember 2022May 2024Allow2010NoNo
17950612NOVEL CERIUM OXIDE NANOCOMPLEX AND A COMPOSITION FOR PREVENTING OR TREATING LIVER FAILURE COMPRISING THE SAMESeptember 2022August 2024Allow2330NoNo
17933929COMPOSITIONS AND USES OF ALPHA-ADRENERGIC AGENTSSeptember 2022April 2025Allow3110NoNo
17903597Ocular surface drug retention agent, eye drop containing the same, and method for retention of ocular surface drug using the same and method for treating ocular diseaseSeptember 2022June 2024Allow2120YesNo
17876811PHOTOCURABLE HYDROGEL LOADED WITH VH298-MODIFIED EXOSOME AND METHOD OF PREPARATION AND USE THEREOFJuly 2022May 2024Allow2210NoNo
17787603COMPOSITION FOR PREVENTING OR TREATING OCULAR DISEASES COMPRISING AMNIOTIC EPITHELIAL CELL DERIVED EXOSOMESJune 2022May 2025Allow3510NoNo
17833019APPLICATION OF ENDOPHYTIC FALCIPHORA ORYZAE FO-R20 IN CONTROLLING PANICLE BLASTJune 2022February 2024Allow2110NoNo
17658644PHYTOREGULATOR FOR PLANTSApril 2022April 2025Abandon3730NoNo
17767804AGROCHEMICAL COMPOSITIONApril 2022April 2025Allow3610NoNo
17656825Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye DisordersMarch 2022February 2025Abandon3520NoNo
17702885GERMINATION/SPROUTING AND FRUIT RIPENING REGULATORSMarch 2022September 2024Allow3021NoNo
17636651SYNERGISTIC HPPD MIXTURESFebruary 2022June 2025Abandon3901NoNo
17632152AQUEOUS FORMULATION THAT REDUCES DAMAGE CAUSED BY SPRING FROSTS IN PLANTS AND PRODUCTION METHOD THEREOFFebruary 2022February 2024Allow2410NoNo
17649469RHEOLOGY MODIFIED LOW FOAMING LIQUID ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOFJanuary 2022November 2024Allow3320NoNo
17582886Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin TherapyJanuary 2022January 2025Abandon3610NoNo
17629267PROCESS FOR THE PREPARATION OF STERILE OPHTHALMIC AQUEOUS FLUTICASONE PROPIONATE FORM A NANOCRYSTALS SUSPENSIONSJanuary 2022April 2025Abandon3910NoNo
17580770Seed CoatingJanuary 2022October 2024Allow3330NoNo
17626313MIXTURES COMPRISING INDAZOLE PESTICIDESJanuary 2022May 2025Allow4011NoNo
17622677USE OF DIHYDROPORPHIN DERIVED FROM CHLOROPHYLL AS PLANT GROWTH REGULATORDecember 2021December 2024Allow3620NoNo
17622576MELANOIDIN COMPOSITIONS FOR PROTECTING CROPS FROM NONFUNGAL PESTSDecember 2021May 2025Abandon4110NoNo
17619311STABLE HERBICIDAL COMPOSITIONS COMPRISING AMINE OXIDE AND BETAINEDecember 2021June 2025Allow4211NoNo
17619565PHARMACEUTICAL COMPOSITION COMPRISING A COLLOIDAL DISPERSION AND METHODS AND USES THEREOFDecember 2021February 2025Abandon3810NoNo
17618931FORMULATIONS AND METHODS FOR CONTROLLING INVASIVE AMPHIBIANSDecember 2021April 2025Allow4020NoNo
17618531FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTSDecember 2021May 2025Allow4111NoNo
17533862PROCESSES AND COMPOSITIONS FOR INCREASING ENZYME CONCENTRATIONS AND DRY MATTER USING REACTIVE OXYGEN SPECIES IN HYDROPONICALLY GROWN CELLULOSIC MATERIALSNovember 2021March 2025Abandon4030NoNo
17612551Vancomycin Liposome Compositions and MethodsNovember 2021March 2025Abandon4010NoNo
17525170HIGH-PURITY THERMOSTABLE CRYSTAL FORM OF SUBSTITUTED 3-ISOXAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOFNovember 2021September 2024Allow3410NoNo
17610263HERBICIDAL COMPOSITIONNovember 2021December 2024Allow3820YesNo
17516845COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOFNovember 2021November 2024Allow3610NoNo
17507593PRESERVATIVE REMOVAL FROM EYE DROPSOctober 2021September 2024Allow3520NoNo
17505029Methods and Compositions for Treating Ulcerative ColitisOctober 2021December 2024Allow3820NoNo
17604892ESTERS OF NON- AROMATIC HETEROCYCLIC COMPOUNDS HAVING A NEMATOCIDAL ACTIVITY, THEIR AGRONOMIC COMPOSITIONS AND USE THEREOFOctober 2021May 2025Abandon4311NoNo
17501854SUPER-RESOLUTION OPTICAL MICROSCOPY USING ALUMINOSILICATE NANOPARTICLESOctober 2021August 2024Allow3411NoNo
17600897PYRIDAZINONE COMPOUND AND HERBICIDEOctober 2021March 2025Abandon4101NoNo
17491687PEROXIDE-LESS BIOPHOTONIC COMPOSITIONS AND METHODSOctober 2021December 2024Abandon3810NoNo
17486308PHARMACEUTICAL COMPOSITIONS COMPRISING FLURBIPROFENSeptember 2021May 2025Abandon4420NoNo
17593749SUBSTITUTED 2-HETEROARYLAMINOBENZENES AND THE SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTSSeptember 2021May 2025Allow4421NoNo
17441748METHOD FOR CONTROLLING WEEDSSeptember 2021February 2025Allow4120NoNo
17441722METHOD FOR CONTROLLING WEEDSSeptember 2021November 2024Allow3810NoNo
17593615FRUIT BLOSSOM END ROT-PREVENTING AGENT COMPRISING NITROPHENOL COMPOUND OR SALT THEREOFSeptember 2021May 2025Abandon4420NoNo
17448151Facile Assembly of Soft Nanoarchitectures and Co-Loading of Hydrophilic and Hydrophobic Molecules via Flash NanoprecipitationSeptember 2021August 2024Allow3510NoNo
17439455Aqueous 1,2-Benzisothiazoline-3-One DispersionsSeptember 2021September 2024Allow3610NoNo
17438871NOVEL 3-(2-BROMO-4-ALKYNYL-6-ALKOXYPHENYL)-3-PYRROLIN-2-ONES AND THEIR USE AS HERBICIDESSeptember 2021January 2025Abandon4001NoNo
17593100SOIL MICROBIAL REGULATOR FOR ENHANCING PLANT STRESS RESISTANCESeptember 2021December 2024Allow3920NoNo
17465546TOPICAL SANITIZING FORMULATIONS AND USES THEREOFSeptember 2021August 2024Allow3510NoNo
17465748Solid Implant Formulation for Drug DeliverySeptember 2021November 2024Abandon3810NoNo
17410523COMPOSITIONS AND METHODS OF MODULATING ENDOCHONDRAL OSSIFICATION AND BONE FORMATIONAugust 2021October 2024Abandon3810NoNo
17411044PERAMIVIR SOLUTION TYPE INHALANT AND PREPARATION METHOD THEREFORAugust 2021October 2024Allow3710NoNo
17431815PYRIDAZINES HERBICIDAL COMPOUNDSAugust 2021January 2025Abandon4101NoNo
17431294PROTOPORPHYRIN IX DERIVATIVES AND USE THEREOF TO IMPROVE THE HEALTH OF PLANTSAugust 2021September 2024Allow3710NoNo
17430411HERBICIDAL COMPOSITIONSAugust 2021January 2025Abandon4110NoNo
17428433HERBICIDAL COMPOUNDSAugust 2021February 2025Abandon4201NoNo
17391495Oral Rapamycin Nanoparticle Preparations and UseAugust 2021October 2024Allow3910NoNo
17388066NANOPARTICLES FOR USE AS A THERAPEUTIC VACCINEJuly 2021May 2025Abandon4520NoNo
17386762SYSTEMS AND METHODS FOR TREATING AND/OR PREVENTING ACNEJuly 2021March 2025Allow4340NoNo
17385480MEDICAL AND NUTRITIONAL COMPOSITIONS AND METHODS OF USEJuly 2021March 2025Abandon4411NoNo
17381464TREATMENT OF SYMPTOMS ASSOCIATED WITH FEMALE GASTROPARESISJuly 2021June 2025Abandon4711NoNo
17378309COMPRESSION RESISTANT IMPLANTS INCLUDING AN OXYSTEROL AND METHODS OF USEJuly 2021August 2024Allow3710NoNo
17361995NOVEL FORMULATION AND TREATMENT METHODSJune 2021June 2024Allow3510YesNo
17304708Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye DisordersJune 2021September 2021Allow310NoNo
17417326METHOD FOR CONTROLLING WEEDJune 2021January 2025Abandon4310NoNo
17304289DOSAGE FORM OF VINCA ALKALOID DRUGJune 2021August 2024Allow3810NoNo
17343471AMORPHOUS CALCIUM CARBONATE STABILIZED WITH POLYPHOSPHATES OR BISPHOSPHONATESJune 2021June 2024Allow3610NoNo
17299409METHYLOBACTERIUM COMPOSITIONS FOR IMPROVING CORN YIELDJune 2021June 2025Allow4811NoNo
17299724HERBICIDAL COMPOSITIONSJune 2021August 2024Allow3810NoNo
17319292COMPOSITIONS OF AMORPHOUS CALCIUM CARBONATE FOR INHALATION, SUBLINGUAL OR BUCCAL ADMINISTRATIONMay 2021June 2024Allow3710YesNo
17236054ORAL SOLUBLE FILM CONTAINING SILDENAFIL CITRATEApril 2021September 2021Allow520NoNo
17285813HETEROARYLAMINOQUINOLINES AND ANALOGUESApril 2021October 2024Abandon4210NoNo
17206890METHODS FOR TREATING OCULAR INFLAMMATORY DISEASESMarch 2021September 2024Abandon4210NoNo
17204743COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA, MILD HYPEROPIA, AND IRREGULAR ASTIGMATISMMarch 2021August 2024Abandon4110NoNo
17200595PRESERVATIVE REMOVAL FROM EYE DROPSMarch 2021July 2021Allow410NoNo
17183553PHARMACEUTICAL SOLUTION OF AMLODIPINEFebruary 2021October 2021Allow820NoNo
17249238Zeaxanthin Formulations With Additional Ocular-Active Nutrients,For Protecting Eye Health And Treating Eye DisordersFebruary 2021May 2021Allow310NoNo
17179650KETOROLAC COMPOSITIONS FOR CORNEAL WOUND HEALINGFebruary 2021August 2024Abandon4210NoNo
17173229MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETOFebruary 2021October 2023Allow3220NoNo
17171624COMPOSITIONS AND METHODS FOR REDUCING BODY FATFebruary 2021August 2024Abandon4210NoNo
17148236VETERINARY PHARMACEUTICAL COMPOSITIONS FOR DIRECT SYSTEMIC INTRODUCTIONJanuary 2021February 2024Allow3710NoNo
17067977ENCAPSULATION OF HERBICIDES TO REDUCE CROP INJURYOctober 2020December 2024Allow5140YesNo
17011888Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin TherapySeptember 2020July 2021Allow1020NoNo
16087757CONTROLLED PRODUCTION OF SPHERICAL CALCIUM PHOSPHATE, MAGNESIUM PHOSPHATE, AND STRONTIUM PHOSPHATE PARTICLES FOR DENTAL AND ORTHOPEDIC APPLICATIONS USING DUAL ASYMMETRIC CENTRIFUGATIONAugust 2020September 2021Allow3610NoNo
16929837COMPOSITIONS OF AMORPHOUS CALCIUM CARBONATE FOR INHALATION, SUBLINGUAL OR BUCCAL ADMINISTRATIONJuly 2020February 2021Allow710NoNo
16907726COMPRESSION RESISTANT IMPLANTS INCLUDING AN OXYSTEROL AND METHODS OF USEJune 2020March 2021Allow910NoNo
16892592NOVEL OCCLUSIVE COMPOSITIONSJune 2020November 2021Allow1810NoNo
16769057EYE MAKE-UP COMPOSITIONS COMPRISING GRAPHENEJune 2020November 2021Allow1820NoNo
16877986PHARMACEUTICAL COMPOSITIONS FOR DIRECT SYSTEMIC INTRODUCTIONMay 2020October 2020Allow510NoNo
16762170DENTAL COMPOSITION WITH HIGH E-MODULUSMay 2020October 2020Allow600NoNo
16868918FORMULATIONS FOR WEIGHT LOSS AND METHODS OF USEMay 2020June 2021Allow1310NoNo
16867319POLYFUNCTIONAL RADICAL SCAVENGER HYDROGEL FORMULATIONMay 2020April 2021Allow1210NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FAY, ZOHREH ALEMZADEH.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
14
Examiner Affirmed
11
(78.6%)
Examiner Reversed
3
(21.4%)
Reversal Percentile
33.4%
Lower than average

What This Means

With a 21.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
29
Allowed After Appeal Filing
7
(24.1%)
Not Allowed After Appeal Filing
22
(75.9%)
Filing Benefit Percentile
29.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 24.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner FAY, ZOHREH ALEMZADEH - Prosecution Strategy Guide

Executive Summary

Examiner FAY, ZOHREH ALEMZADEH works in Art Unit 1617 and has examined 422 patent applications in our dataset. With an allowance rate of 66.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 25 months.

Allowance Patterns

Examiner FAY, ZOHREH ALEMZADEH's allowance rate of 66.8% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by FAY, ZOHREH ALEMZADEH receive 1.96 office actions before reaching final disposition. This places the examiner in the 64% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by FAY, ZOHREH ALEMZADEH is 25 months. This places the examiner in the 64% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a -4.1% benefit to allowance rate for applications examined by FAY, ZOHREH ALEMZADEH. This interview benefit is in the 4% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 21.3% of applications are subsequently allowed. This success rate is in the 16% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 48.5% of cases where such amendments are filed. This entry rate is in the 68% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 44.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 37% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 48.1% of appeals filed. This is in the 10% percentile among all examiners. Of these withdrawals, 69.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 78.1% are granted (fully or in part). This grant rate is in the 91% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 31.9% of allowed cases (in the 96% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.